FITEC II completes its second investment with a €10 million capital increase to support the expansion of the Turin-based company
The objective is to support the commercial expansion of the company, and the development of new innovative products
Milan, 10th September 2024 – Fondo Italiano d’Investimento SGR announces the completion of a €10 million capital increase to acquire a minority stake in Intrauma SpA, a leading developer, manufacturer, and distributor of orthopedic medical devices specializing in traumatology.
This transaction marks the second investment by FITEC II, the second-generation fund of Fondo Italiano Tecnologia e Crescita, which invests with a growth capital strategy in Italy’s high-tech companies through expansion projects, product innovation, and enhanced competitive positioning.
Founded in 2006 by the Del Medico family, Intrauma is an Italian manufacturer of advanced orthopedic devices with a focus on traumatology for both human and veterinary applications. With a cutting-edge product portfolio, the Rivoli (Turin)-based company has established a strong market presence and continues to expand its international footprint. Intrauma employs over 100 people and serves a portfolio of more than 700 clients, including prominent healthcare companies, hospitals, clinics, and distributors in Italy and internationally. In 2023, the company generated over €21 million in revenue, a 23% increase compared to 2022, alongside investments exceeding €2 million.
The capital infusion will fuel Intrauma’s commercial growth and facilitate the expansion of its product offerings, including innovations such as silver coatings, prosthetics, and advancements in regenerative medicine.
Claudio Catania, Senior Partner at Fondo Italiano, commented:
“The FITEC team is proud to support Intrauma and its experienced management as they embark on this new phase of development. This investment aligns with our mission to accelerate the growth of top Italian companies, particularly in strategic sectors like healthcare, where strong leadership plays a vital role.”
Riccardo Del Medico, CEO of Intrauma, added:
“FITEC’s investment brings valuable resources and financial backing to help us achieve our ambitious growth targets for 2029. I extend my sincere thanks to our General Manager, Dr. Paolo Chiavario, as well as to all our employees, collaborators, and advisors at Intrauma S.p.A. for their contributions in reaching this important milestone.”
Fondo Italiano d’Investimento was supported in the transaction by Portolano Cavallo for legal due diligence, PWC for financial, tax, and ESG due diligence, and Sigma Experience for business due diligence.
Intrauma S.p.A. was advised by Aritma and financial advisors Dr. Guido Richetti and Dr. Mario Balbo, with tax matters handled by Studio Piermarioli and legal aspects managed by Studio Legale Tavarelli.
